Posted by Michael Wonder on 01 Aug 2018
Lundbeck and Otsuka’s Rxulti (brexpiprazole) approved by the European Commission
31 July 2018 - Rxulti (brexpiprazole) has been approved for the treatment of schizophrenia in adults.
Lundbeck) and Otsuka today announce that the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adults. The approval follows the positive opinion issued by the CHMP on 31 May 2018.
Lundbeck and Otsuka will now work with local pricing and reimbursement bodies in countries throughout Europe to help ensure that eligible patients are able to access Rxulti. The medicine is expected to be made available in the first EU markets during first half of 2019.
